title: Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice.
abstract: Hepatitis C virus (HCV) is a worldwide problem which does not have an effective vaccine and more than 170 million people worldwide are chronically infected by HCV. T cell responses are associated with spontaneous clearance of HCV infection. We report here the development of recombinant Lambda bacteriophage nanoparticles encoding HCV Core antigen. The aim of this study was to investigate the antigen-specific immune responses triggered in mice by different prime-boost combinations of DNA and Lambda phage nanoparticles encoding the HCV Core. The homologous prime/boost with recombinant Lambda nanoparticles induced higher levels of cellular and humoral immune response than the DNA vaccines. However, a heterologous prime/boost of HCV Core protein, using DNA vaccine priming followed by Lambda boost, induced highest level of lymphocyte proliferation, CD8 lymphocytes with cytotoxic function, and shifting the immune response toward a T helper (Th1) pattern and in overall improved immunity. Our study provides a new, safe, and effective vaccine for the prime-boost regimen which augments robust immunity and highlights novel promising strategies in HCV vaccine development.
authors.affiliation: Golestan Research Center of Gastroenterology and Hepatology-GRCGH, Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran.
authors.forename: Atefeh
authors.initials: A
authors.lastname: Saeedi
authors.forename: Amir
authors.initials: A
authors.lastname: Ghaemi
authors.forename: Alijan
authors.initials: A
authors.lastname: Tabarraei
authors.forename: Abdolvahab
authors.initials: A
authors.lastname: Moradi
authors.forename: Ali
authors.initials: A
authors.lastname: Gorji
authors.forename: Shahryar
authors.initials: S
authors.lastname: Semnani
authors.forename: Hoorieh
authors.initials: H
authors.lastname: Soleimanjahi
authors.forename: Ahmad Hosseinzadeh
authors.initials: AH
authors.lastname: Adli
authors.forename: Seyed Yones
authors.initials: SY
authors.lastname: Hosseini
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Vakili
mesh_terms: D000818:Animals; D010582:Bacteriophage lambda / Q000235:genetics*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D049109:Cell Proliferation; D004337:Drug Carriers; D005260:Female; D005822:Genetic Vectors; D016174:Hepacivirus / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood; D008810:Mice, Inbred C57BL; D053758:Nanoparticles; D014611:Vaccination / Q000379:methods*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014758:Viral Core Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
chemical_list: D004337:Drug Carriers; D018937:Hepatitis C Antibodies; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D014765:Viral Vaccines; C069130:nucleocapsid protein, Hepatitis C virus
references.citation: Immunol Rev. 2011 Jan;239(1):99-108
references.pmid: 21198667
references.citation: Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):383-5
references.pmid: 19575020
references.citation: Public Health Genomics. 2013;16(4):192-7
references.pmid: 23859951
references.citation: Vaccine. 2004 Jun 23;22(19):2413-9
references.pmid: 15193403
references.citation: Proc Natl Acad Sci U S A. 2007 May 15;104(20):8427-32
references.pmid: 17485666
references.citation: J Viral Hepat. 2012 Jul;19(7):449-64
references.pmid: 22676357
references.citation: FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):21-6
references.pmid: 14734182
references.citation: FEMS Immunol Med Microbiol. 2011 Mar;61(2):197-204
references.pmid: 21204995
references.citation: Front Microbiol. 2013 Jul 26;4:213
references.pmid: 23898329
references.citation: Gastroenterology. 2004 Sep;127(3):924-36
references.pmid: 15362047
references.citation: J Hepatol. 2011 Jun;54(6):1273-85
references.pmid: 21236312
references.citation: Vaccine. 2011 May 9;29(20):3714-23
references.pmid: 21396407
references.citation: J Virol. 2004 Sep;78(17):9093-104
references.pmid: 15308705
references.citation: Vaccine. 2003 Nov 7;21(31):4555-64
references.pmid: 14575768
references.citation: J Infect Dis. 2013 Sep;208(6):1008-19
references.pmid: 23776192
references.citation: Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30
references.pmid: 17392433
references.citation: Annu Rev Pathol. 2006;1:23-61
references.pmid: 18039107
references.citation: Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294-8
references.pmid: 7509068
references.citation: Biochem Biophys Res Commun. 2002 Oct 4;297(4):779-86
references.pmid: 12359220
references.citation: Vaccine. 2004 Apr 16;22(13-14):1666-71
references.pmid: 15068849
references.citation: Nat Rev Genet. 2000 Nov;1(2):91-9
references.pmid: 11253666
references.citation: Vaccine. 2007 Oct 16;25(42):7339-53
references.pmid: 17875349
references.citation: Gastroenterology. 2008 May;134(5):1385-95
references.pmid: 18471515
references.citation: Intervirology. 2011;54(3):105-12
references.pmid: 20956855
references.citation: Nat Med. 2006 Feb;12(2):190-7
references.pmid: 16462801
references.citation: Vaccine. 2004 Apr 16;22(13-14):1656-65
references.pmid: 15068848
references.citation: Genet Vaccines Ther. 2010 May 12;8:3
references.pmid: 20459865
references.citation: J Virol. 2002 Jun;76(12):6138-46
references.pmid: 12021347